Nyrada Inc Total Assets
Nyrada Inc total assets. Based on the latest financial reports, Nyrada Inc (NYR) holds total assets worth AU$10.39 Million AUD (≈ $7.35 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Nyrada Inc for the company's overall valuation and market capitalisation.
Total Assets of Nyrada Inc (2018–2025)
Total assets of Nyrada Inc from 2018 to 2025. This chart illustrates how Nyrada Inc's total assets have evolved over time, based on quarterly financial data. See NYR stock price for real-time trading data and today's change.
Nyrada Inc - Asset Composition Analysis
Nyrada Inc Total Assets Breakdown (June 2025)
Nyrada Inc total assets breakdown as of June 2025. Nyrada Inc's total assets of AU$10.39 Million consist of 99.5% current assets and 0.6% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 55.3% |
| Accounts Receivable | AU$2.29 Million | 43.1% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$29.04K | 0.6% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Nyrada Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NYR working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nyrada Inc's current assets represent 99.5% of total assets in 2025, an increase from 98.7% in 2018.
- Cash Position: Cash and equivalents constituted 55.3% of total assets in 2025, down from 98.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 43.1% of total assets.
Nyrada Inc Competitors by Total Assets
Key competitors of Nyrada Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Nyrada Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.00 | 10.00 | 5.50 |
| Quick Ratio | 19.00 | 10.00 | 5.50 |
| Cash Ratio | 0.00 | 8.79 | 5.45 |
| Working Capital | AU$9.82 Million | AU$5.85 Million | AU$3.35 Million |
Nyrada Inc - Advanced Valuation Insights
This section examines the relationship between Nyrada Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 50.61 |
| Latest Market Cap to Assets Ratio | 15.86 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | AU$5.30 Million |
| Market Capitalization | $84.06 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nyrada Inc's assets at a significant premium (15.86x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Nyrada Inc's assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nyrada Inc (2018–2025)
The table below shows the annual total assets of Nyrada Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$5.30 Million ≈ $3.75 Million |
-10.28% |
| 2024-06-30 | AU$5.91 Million ≈ $4.18 Million |
+14.38% |
| 2023-06-30 | AU$5.16 Million ≈ $3.65 Million |
-57.01% |
| 2022-06-30 | AU$12.01 Million ≈ $8.50 Million |
-20.73% |
| 2021-06-30 | AU$15.16 Million ≈ $10.72 Million |
+141.84% |
| 2020-06-30 | AU$6.27 Million ≈ $4.43 Million |
+448.25% |
| 2019-06-30 | AU$1.14 Million ≈ $808.85K |
-63.94% |
| 2018-06-30 | AU$3.17 Million ≈ $2.24 Million |
-- |
About Nyrada Inc
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more